The FDA approved isatuximab-irfc (Sarclisa, Sanofi) in combination with pomalidomide (Pomalyst, Celgene) and dexamethasone (pom-dex) for the treatment of adults with relapsed/refractory multiple myeloma (RRMM) who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
MARCH 3, 2020